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AIMS OF THE STUDY 
 
1. To evaluate the clinical, bacteriological and radiological pattern of                          
tuberculosis infection among HIV seropositive individuals in correlation 
with the CD 4+ counts. 
 
2. To find out the trend of Tuberculosis infection, in HIV seropositive patients 
in Thanjavur Medical College, a rural center.  
 
3. To Find out the prevalence of Pulmonary Tuberculosis among HIV 
Seropositives in Thanjavur Medical College.  
 
BACKGROUND OF THE STUDY 
 
Tuberculosis is a life threatening, transmissible and pandemic disease 
especially among millions of the HIV infected patients. In developing 
countries like India, where HIV infection is becoming prevalent and where 
Tuberculosis infection has long been endemic, its incidence is increasing.  
The following studies were conducted in HIV and Tuberculosis co-infection 
in INDIA. 
 
1. The trend of HIV infection in patients with pulmonary tuberculosis in 
South India by Solomon, Anuradha, Dr. S. Rajashekar. 
2. The trend of HIV infection in patients with Tuberculosis in rural south 
India by Dr. S. Rajashekar, A. Uma, A.S. Kamatchi  
3.  A study on HIV and TB- a comparitive study by Beena susheel and 
Pai. 
4.  Prevalence of TB among HIV seropositives in Kolkata by M.K. 
Bhattarcharya and K. Sarkar.   
 
HIV infected persons are in five-fold risk of developing Tuberculosis than 
the general population and every third HIV infected person dies of 
Tuberculosis worldwide. 
However no information is available about the prevalence of Tuberculosis 
among HIV seropositives in Thanjavur Medical College, a rural center in 
South India, which caters to the needs of about ten districts of Tamil Nadu.  
 
INTRODUCTION 
 
Human immuno deficiency virus infection is becoming a pandemic 
affecting millions of people in the sub Saharan, South and South East Asian 
regions. 
Human immuno deficiency virus infection has superseded other 
diseases and has become the major killer disease in the recent past.  
Human immuno deficiency virus enters into the human body and 
destroys the immune frame work thereby predisposing to other infections 
In developing countries like India where tuberculosis is already a known 
endemic this growing trend of Human immuno deficiency virus infection 
becomes significant. 
About one third to one half of the patients with Human immuno 
deficiency virus infection is co infected with tuberculosis and the mortality 
is more in this group. 
So the need of the hour lies in tackling tuberculosis efficiently in 
persons with Human immuno deficiency virus infection and reducing the 
mortality in the above group. 
 
 
TUBERCULOSIS: an overview 
Tuberculosis has been present in humans since antiquity, as the origins of the 
disease are in the first domestication of cattle (which also gave humanity viral 
poxes). Skeletal remains show prehistoric humans (4000 BC) had TB and 
tubercular decay has been found in the spines of Egyptian mummies from 3000-
2400 BC. There were references to TB in India around 2000 BC, and 
indications of lung scarring identical to that of modern-day TB sufferers in 
preserved bodies (such as mummies) suggests that TB was present in The 
Americas from about 2000 BC 
Phthisis is a Greek term for consumption. Around 460 BC, Hippocrates 
identified phthisis as the most widespread disease of the times which was 
almost always fatal. 
Due to the variety of its symptoms, TB was not identified as a single disease 
until the 1820s and was not named 'tuberculosis' until 1839 by J. L. Schönlein. 
The bacillus-causing tuberculosis, Mycobacterium tuberculosis, was identified 
and described on March 24, 1882 by Robert Koch. He received the Nobel Prize 
in physiology or medicine in 1905 for this discovery. 
 
The other names for tuberculosis are: 
TB (short for tuberculosis and also for Tubercle Bacillus)  
Consumption (TB seemed to consume people from within with its 
symptoms of bloody cough, fever, pallor, and long relentless wasting)  
Wasting disease   
White plague (TB sufferers appear markedly pale)  
Phthisis (Greek for consumption) and phthisis pulmonalis  
 King's evil   
Miliary TB (x-ray lesions look like millet seeds)  
 Koch's Disease named after Robert Koch who discovered the tuberculosis 
bacilli. 
Pathogenesis 
While only 10% of TB infection progresses to TB disease, if untreated the death 
rate is 51%. 
TB infection begins when MTB bacilli reach the pulmonary alveoli, infecting 
alveolar macrophages, where the mycobacteria replicate exponentially. The 
primary site of infection in the lungs is called the Ghon focus. Bacteria are 
picked up by dendritic cells, which can transport the bacilli to local 
(mediastinal) lymph nodes, and then through the bloodstream to the more 
distant tissues and organs where TB disease could potentially develop: lung 
apices, peripheral lymph nodes, kidneys, brain, and bone. 
Tuberculosis is classed as one of the granulomatous inflammatory conditions. 
Macrophages, T lymphocytes, B lymphocytes and fibroblasts are among the 
cells that aggregate to form a granuloma, with lymphocytes surrounding 
infected macrophages. The granuloma functions not only to prevent 
dissemination of the mycobacteria, but also provides a local environment for 
communication of cells of the immune system. Within the granuloma, T 
lymphocytes (CD4+) secrete a cytokine such as interferon gamma, which 
activates macrophages to destroy the bacteria with which they are infected, 
making them better able to fight infection. T lymphocytes (CD8+) can also 
directly kill infected cells. 
Importantly, bacteria are not eliminated with the granuloma, but can become 
dormant, resulting in a latent infection. Latent infection can be diagnosed only 
by tuberculin skin test, which yields a delayed hypersensitivity type response to 
purified protein derivatives of M. tuberculosis in an infected person. 
Another feature of the granulomas of human tuberculosis is the development of 
cell death, also called necrosis, in the center of tubercles. To the naked eye this 
has the texture of soft white cheese and was termed caseous necrosis. 
If TB bacteria gain entry to the blood stream from an area of tissue damage they 
spread through the body and set up myriad foci of infection, all appearing as 
tiny white tubercles in the tissues. This is called miliary tuberculosis and has a 
high case fatality. 
Progression 
In those people in whom TB bacilli overcome the immune system defenses and 
begin to multiply, there is progression from TB infection to TB disease. This 
may occur soon after infection (primary TB disease – 1 to 5%) or many years 
after infection (post primary TB, secondary TB, reactivation TB disease of 
dormant bacilli – 5 to 9%). 
About five percent of infected persons will develop TB disease in the first two 
years, and another five percent will develop disease later in life. In other words, 
about 10% of infected persons with normal immune systems will develop TB 
disease in their lifetime. 
Some medical conditions increase the risk of progression to TB disease. In HIV 
infected persons with TB infection, the risk increases to 10% each year instead 
of 10% over a lifetime. Other such conditions include drug injection (mainly 
because of the life style of IV Drug users), substance abuse, recent TB infection 
(within two years) or history of inadequately treated TB, chest X-ray suggestive 
of previous TB (fibrotic lesions and nodules), diabetes mellitus, silicosis, 
prolonged corticosteroid therapy and other immunosuppressive therapy, head 
and neck cancers, hematologic and reticuloendothelial diseases (leukemia and 
Hodgkin's disease), end-stage renal disease, intestinal bypass or gastrectomy, 
chronic malabsorption syndromes, or low body weight (10% or more below the 
ideal). 
TB disease most commonly affects the lungs (75% or more), where it is called 
pulmonary TB. Symptoms include a productive, prolonged cough of more than 
three weeks duration, chest pain, and hemoptysis. Systemic symptoms include 
fever, chills, night sweats, appetite loss, weight loss, and easy fatigability.  
Diagnosis 
A complete medical evaluation for TB includes a medical history, a physical 
examination, a tuberculin skin test, a serological test, a chest X-ray, and 
microbiologic smears and cultures. Bacteriophage-based assays are among a 
few new testing procedures that offer the hope of cheap, fast and accurate TB 
testing for the impoverished countries that need it most. 
HIV – an introduction.1 
In 1981, the first cluster of cases that we now call AIDS was recognized and 
reported. Nearly all of the early identified cases were in young homosexual 
men, but it was quickly learned that HIV infection could be transmitted by 
heterosexual contact and by blood transfer from infected to non infected 
individuals. 
 
The clinical consequences of human immunodeficiency virus (HIV) infection 
are due to the ability of this virus to disarm the host immune system, a process 
that occurs by virtue of the fact that the primary target for the virus is the 
helper-inducer subset of lymphocytes. This lymphocyte subset, defined by its 
surface expression of the CD4 molecule, acts as the pivotal orchestrator of a 
myriad of immune functions. HIV infection can therefore be considered a 
disease of the immune system, characterized by the progressive loss of CD4-
positive (CD4+) lymphocytes, with ultimately fatal consequences for the 
infected host. 
 
Despite this immunosuppression induced by HIV, a number of specific 
immunologic defenses against the virus are generated in infected individuals 
and may contribute to the long asymptomatic phase following infection by 
keeping the virus at least partially contained. 
The hallmark of HIV infection is progressive depletion of the CD4 helper-
inducer subset of lymphocytes. Because of the central role of these cells in 
immunologic functioning, the clinical disease manifestations of 
immunosuppression and susceptibility to opportunistic infections and 
neoplasms are not surprising. The immunologic deficits associated with HIV 
infection are widespread and involve numerous interdependent effector arms of 
the immune system, including both cellular and humoral elements. 
 
Of all the opportunistic infections in persons infected with HIV virus 
tuberculosis remains the commonest. 
 
HIV probably increases susceptibility to infection with M. tuberculosis. 
HIV increases the risk of progression of M. tuberculosis infection to TB 
disease. This risk increases with increasing immunosuppression. HIV 
increases not only the risk but also the rate of progression of recent or 
latent M. tuberculosis infection to disease. 
 
 
 
 
 
  
 
 
 
 
Shown above is the diagram of the Human immunodeficiency virus showing 
the envelope glycoprotein and reverse transcriptase enzyme.  
 
WHO clinical staging system for HIV infection and related 
disease in adults (13 years or older)2 
Stage 1:  º Asymptomatic 
º Persistent generalized lymphadenopathy 
Performance scale 1: asymptomatic, normal activity 
Stage 2:       º Weight loss < 10% of body weight 
º Minor mucocutaneous manifestations 
(e.g. oral ulcerations, fungal nail infections) 
º Herpes zoster within the last 5 years 
º Recurrent upper respiratory tract infections 
(e.g. bacterial sinusitis) 
and/or Performance scale 2: symptomatic, normal activity 
Stage 3:  º Weight loss > 10% of body weight 
º Unexplained chronic diarrhoea for more than 1 month 
º Unexplained prolonged fever for more than 1 month 
º Oral candidiasis (thrush) 
º Oral hairy leukoplakia 
º Pulmonary TB 
º Severe bacterial infections (pneumonia, pyomyositis) 
and/or Performance scale 3: bedridden < 50% of the day 
during the last month 
Stage 4: º HIV wasting syndrome. 
º Pneumocystis carinii pneumonia 
º Toxoplasmosis of the brain 
º Cryptosporidiosis with diarrhoea, for more than 1 month 
º Cryptococcosis, extrapulmonary 
º Cytomegalovirus (CMV) disease of an organ other than 
liver, spleen, lymph nodes 
º Herpesvirus infection, mucocutaneous for more than 1 
month, or visceral any duration 
º Progressive multifocal leukoencephalopathy (PML) 
º Any disseminated endemic fungal infection 
(e.g. histoplasmosis) 
 
WHO case definitions for AIDS surveillance in adults and children 
where HIV testing facilities are not available 
Adults 
The case definition for AIDS is fulfilled if at least 2 major signs and at 
least 1 minor sign are present. 
Major signs 
º Weight loss > 10% of body weight 
º Chronic diarrhoea for more than 1 month 
º prolonged fever for more than 1 month 
Minor signs 
º Persistent cough for more than 1 month 
º generalized pruritic dermatitis 
º History of herpes zoster 
º oropharyngeal candidiasis 
º Chronic progressive or disseminated herpes simplex infection 
º generalized lymphadenopathy 
The presence of either generalized Kaposi sarcoma or cryptococcal 
meningitis is sufficient for the case definition of AIDS. 
The advantages of this case definition are that it is simple to use and 
inexpensive. The disadvantages are its relatively low sensitivity and 
specificity. For example, HIV-negative TB cases could be counted as AIDS 
cases because of their similarity in clinical presentation. 
PRACTICAL POINT 
The term AIDS is used for epidemiological surveillance, not 
for clinical care.  a for patients with TB, persistent cough for more than 1 
month should not be considered as a minor sign. 
 RISK OF HIV IN TB PATIENTS 
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FEATURES AND CLINICAL PRESENTATION IN RELATION TO STAGE OF HIV 
INFECTION 
TB 20 Million 
HIV 
4 Million 
 
?Atypical presentation, often 
infiltrates 
?Lower lung-field lesions, 
intra-thoracic lymph nodes & 
infrequent cavities 
Often shows 
cavities 
Chest X-ray 
Appearance 
Often negative Often positive Sputum Smear 
Result 
Often resembles Primary TB 
Extra pulmonary TB common 
Often resembles 
Post-primary TB 
(Adult-type) 
Clinical 
Presentation  
Late Early 
Stage of HIV infection  
Features 
HIV AND 
TB 2 million 
 Tuberculosis in HIV infection: 
HIV has had a substantial effect on the incidence, clinical manifestations, 
treatment, and outcome of TB. Globally, HIV and TB are the 2 leading 
infectious causes of death. 
People who are infected with HIV are at an increased risk of contracting 
tuberculosis. The WHO estimates that just over 20 million people are currently 
infected with HIV and of these 6 million are co-infected with Mycobacterium 
tuberculosis so Tuberculosis remains an important problem in patients with 
human immunodeficiency virus (HIV) infection. 
Co infection with these pathogens can be particularly devastating, 
especially in the developing world, where the burden of disease is high and 
access to effective therapy is low. 
Among infections associated with HIV, tuberculosis (TB) is unique in 
that it may be transmitted to immunocompetent persons via the respiratory 
route, is easily treatable once identified, may occur in early-stage HIV disease, 
and is preventable with drug therapy.  
However, multi drug resistance is a potentially serious problem, even though its 
incidence has declined because of the use of directly observed therapy and other 
improved practices. 
 
TB is a major opportunistic infection in HIV-infected patients, often 
representing their AIDS-defining illness and the first indication of 
immunodeficiency. Epidemiology, clinical manifestations, and management of 
TB are altered in HIV-infected patients. 
Impact of HIV on TB 
HIV is the most significant risk factor for progression from sub clinical 
infection with Mycobacterium tuberculosis to active TB 3,4.  
However, when a person is dually infected with HIV and M. tuberculosis, 
the risk of developing TB significantly increases from 10% in a life time to 
5%–15% per year5 -8. HIV-infected persons are at markedly increased risk for 
primary or reactivation tuberculosis9, 10 and for second episodes of tuberculosis 
from exogenous reinfection.11 The lifetime risk for progressing to active TB 
among HIV-negative persons latently infected with M. tuberculosis is estimated 
at 10%. In contrast, among HIV-infected persons, the risk for progressing to 
active disease is approximately 10% per year, 12 and the immediate risk for 
progressive primary disease after recent infection with M. tuberculosis 
approaches 40%.13 This interaction between TB and HIV accounts for much of 
the recent global resurgence in TB. Of note, however, HIV infection does not 
increase the infectiousness of persons with active TB.14 The introduction of 
potent combination antiretroviral therapy in the developed world, which has 
dramatically decreased the risk for opportunistic infections and death among 
HIV-infected persons, has also decreased the risk for developing active TB15 
and the risk for death among HIV-infected persons who develop active TB16. 
 
   
Epidemiology  
The frequency with which HIV and Mycobacterium tuberculosis 
infection occur together is determined by the epidemiology of each disease in a 
given population. Highest rates are found in the homeless, injecting drug users, 
and recent immigrants and refugees17. 
The incidence of TB in HIV-infected persons is more than 100 times that 
of the general population. In untreated HIV-infected persons who have a 
positive tuberculin skin test, the risk of active TB is about 8% per year 18. 
Nosocomial transmission of TB from HIV-infected patients to 
healthcare workers has been reported 19. 
One of the most threatening features of TB in HIV-infected patients has 
been the spread of multi drug-resistant (MDR) organisms 20. MDR TB is 
defined as disease that is resistant to at least two drugs (INH and Rifampicin). 
Its incidence has declined dramatically in recent years with more rapid case 
identification, improved isolation practices, use of early empirical therapy with 
drugs directed against MDR strains 21, and use of directly observed therapy 22 
Pathogenesis  
Tuberculosis can develop through progression of recently acquired 
infection (primary disease), reactivation of latent infection, or exogenous 
reinfection. 
Infection with M tuberculosis can occur when an individual exposed to 
an infectious case of tuberculosis inhales particles (<5 µm in size) containing 
the tubercle bacilli.23 If the bacilli reach the pulmonary alveoli, they may be 
ingested by alveolar macrophages, the first line of defense against M 
tuberculosis. Surviving tubercle bacilli multiply within the macrophage and 
eventually undergo hematogenous spread to other areas of the body. 
Once infection does occur, however, the risk of rapid progression is 
much greater among persons with HIV infection, because HIV impairs the 
host's ability to contain new tuberculous infection. 
       Immunocompetent individuals infected with M tuberculosis have 
approximately a 10% lifetime risk of developing tuberculosis, 24 with half of the 
risk occurring in the first 1-2 years after infection. 
 CD4 cell-mediated immunity and macrophage function are essential in 
the control of M tuberculosis infection. During primary infection of an 
immunocompetent host, cell-mediated immunity usually develops and arrests 
progression of disease. About 5% of patients whose primary infection is 
controlled have reactivation years to decades later. In another 5% of patients, 
infection is not contained, and primary pulmonary, extra pulmonary or 
disseminated TB can occur.  
Susceptibility to tuberculosis is related to the pattern of cytokines produced by 
T lymphocytes. CD4+ lymphocytes, which produce interferon- , are central to 
antimycobacterial immune defenses, and fatal mycobacterial disease develops 
in children who lack the interferon-  receptor.25 In contrast to CD4+ 
lymphocytes, CD8+ lymphocytes, which produce interleukin-4 and interleukin-
10, do not contribute to antimycobacterial immunity.26 When peripheral-blood 
lymphocytes from HIV-infected patients with tuberculosis are exposed to 
Mycobacterium tuberculosis in vitro, they produce less interferon-  but similar 
amounts of interleukin-4 and interleukin-10, as compared with lymphocytes 
from HIV-negative patients with tuberculosis.27 These findings suggest that the 
reduced CD4+ response in HIV-infected patients contributes to their 
susceptibility to tuberculosis.  
The hallmark of HIV infection is progressive deterioration and depletion 
of CD4 cells, coupled with defects in macrophage and monocyte function 28. 
There is evidence that the immune response in patients with TB might enhance 
HIV viral replication and accelerate the natural progression of HIV infection 29. 
The risk of TB developing in an HIV-infected patient who is latently co-
infected with M tuberculosis approaches 10% per year, as opposed to a 10% 
lifetime risk in an immunocompetent host 30. Patients with more advanced HIV 
infection (CD4   count, <200 cells/mm3) who are newly infected with 
M.tuberculosis may lack the ability to contain the primary infection, which can 
progress rapidly and is fatal if not treated. Infection with M tuberculosis in an 
immunocompetent person is thought to confer significant protective immunity 
against exogenous reinfection.24 However, reinfection has been reported in 
HIV-seronegative31,32 and -seropositive individuals,33-37 although its incidence is 
not known 
Tuberculosis and the Course of HIV Infection  
Exposure of alveolar macrophages and lymphocytes from HIV-infected patients 
to M. tuberculosis in vitro up-regulates retroviral replication.38,39  
TB has been associated with a 5- to 160-fold increase in HIV viral replication, 
which may decrease after successful TB treatment.40  
 Pleural fluid from patients with tuberculosis increases HIV replication in 
activated lymphocytes,41 and in HIV-infected patients with pulmonary 
tuberculosis, the concentrations of retroviral RNA in bronchoalveolar-lavage 
fluid are highest in areas of tuberculous involvement.42 M. tuberculosis 
probably increases HIV replication by inducing macrophages to produce tumor 
necrosis factor , interleukin-1, and interleukin-6.41,42  
Clinical studies have shown the detrimental effects of tuberculosis on the 
course of HIV infection. The risk of death in HIV-infected patients with 
tuberculosis was reported to be twice that in HIV-infected patients without 
tuberculosis, independently of the CD4 cell count.43 The high mortality rate 
among patients with tuberculosis appeared to be due to progressive HIV 
infection rather than tuberculosis. The degree of immunosuppression is the most 
important predictor of survival in HIV-infected patients with tuberculosis, since 
negative tuberculin skin tests, prior opportunistic infections, and low CD4 cell 
counts are associated with increased mortality.44,45 
Clinical presentation  
 Unlike other opportunistic infections, TB can occur in persons with 
early-stage HIV infection (CD4 count, >300 cells/mm3). Clinical presentation 
of TB in such patients is similar to that in healthy hosts with reactivation 
disease 46. Patients are less likely to present with extrapulmonary disease at this 
stage of HIV infection. Because of the increased virulence in immunocompetent 
hosts of M tuberculosis compared with other opportunistic pathogens (e.g., 
Pneumocystis jiroveci), tuberculosis can occur early in the course of HIV 
infection. In several studies of HIV-infected patients with pulmonary 
tuberculosis, the median CD4 T-cell count was >300 cells/mm3. (38) However, 
in patients with primarily extrapulmonary involvement or disseminated disease, 
the CD4 T-cell count may be much lower. For example, two studies in African 
patients with disseminated disease found the median CD4 T-cell count to be 
<80 cells/mm3.47 A prospective study in the United States,48 found the  median 
CD4 T-cell count to be 144 cells/mm3 (range 2-543) in HIV-infected patients 
with all forms 
 of tuberculosis. Although tuberculosis can be a relatively early manifestation of 
HIV-1 infection, it is important to note that the risk of developing tuberculosis, 
and of disseminated infection, increases as the CD4 T-cell count decreases. 
   Typical symptoms include fever, weight loss, productive cough of 
several weeks' duration, and hemoptysis. Chest radiographs demonstrate the 
presence of focal infiltrates and/or cavitation involving the upper lobes.  
 In patients with advanced HIV disease, TB may present atypically and 
extrapulmonary TB is more common. Disseminated disease with involvement 
of bone marrow, bone, urinary and gastrointestinal tracts, liver, regional lymph 
nodes, and the central nervous system is common 30, 46.  
Radiographic Findings 
 The chest radiograph is the cornerstone of diagnosis for pulmonary 
tuberculosis. Upper lobe infiltrates and cavities are the typical findings in 
reactivation tuberculosis, whereas intrathoracic lymphadenopathy and lower 
lobe disease are seen in primary tuberculosis. In HIV-infected persons with 
higher CD4 T-cell counts (e.g., >200 cells/mm3) the radiographic pattern tends 
to be one of reactivation disease with upper lobe infiltrates with or without 
cavities. 49 In HIV-infected persons who have a greater degree of 
immunosuppression (e.g., CD4 T-cell count <200 cells/mm3), a pattern of 
primary disease with intrathoracic lymphadenopathy and lower lobe infiltrates 
is seen (Figure 2 and Figure 3). As chest radiographs may appear normal in 7-
14% of cases, a high index of suspicion must be maintained in evaluating an 
HIV-infected patient with symptoms suggestive of tuberculosis. 50,51 .The 
finding of low-density lymph nodes with peripheral enhancement on a contrast-
enhanced chest computed tomography (CT) scan is highly predictive of 
tuberculosis. 
Chest radiographs may be normal or show evidence of perihilar or 
mediastinal lymphadenopathy without parenchymal lung involvement. 
Radiographs and   clinical presentation may mimic community-acquired 
pneumonia or Pneumocystis carinii pneumonia. Cavitation is unusual at this 
stage of advanced immunosuppression, and infiltrates more often are diffuse or 
interstitial.  Mycobacterial blood cultures may yield M tuberculosis in one third 
of patients with advanced HIV immunosuppression 52 a severely 
immunocompromised person presenting with TB may not show cavitation and 
may have only mild interstitial infiltrates. Pneumonia, lung tumors, and fungal 
masses may also occur at the site of previously healed TB or granulomatous 
lesions. 
Testing for HIV Infection in Patients with Tuberculosis  
All patients with tuberculosis should be tested for HIV co infection because of 
the potential benefits of an early diagnosis of HIV infection.53  
Selective HIV testing in patients with tuberculosis is unwise, because health 
care providers often fail to identify risk factors for HIV related to heterosexual 
transmission.54 Even when patients with tuberculosis are questioned about risk 
factors for HIV infection, up to 5 percent of those who report no risk factors are 
infected with HIV.54 
 
 
Diagnosis  
 In patients with TB and HIV infection, special consideration is required 
in assessing results of tuberculin skin test and acid-fast bacillus smear and 
culture.  
Tuberculin skin test 
           HIV infection causes depression of cell-mediated immunity, which can 
reduce the sensitivity and reliability of the tuberculin skin test. Only 30% to 
50% of HIV-infected patients who are co infected with M tuberculosis have a 
positive result on the tuberculin skin test 46. Although a positive result increases 
the likelihood of TB, a negative result does not exclude the diagnosis.  
 
Therefore, diagnostic evaluation for TB should be undertaken in all 
patients who have clinical features compatible with TB, regardless of the results 
of the tuberculin skin test. Several cohort studies have demonstrated a high 
incidence of active tuberculosis among HIV-infected individuals with positive 
tuberculin skin test results.   
 There are recent reports of restoration of delayed hypersensitivity on 
skin testing, including tuberculin skin testing in HIV-infected patients who 
begin highly active antiretroviral therapy. This reaction reflects restoration of 
the anti-M tuberculosis cell-mediated immune response, a phenomenon that 
usually occurs within the first month of therapy 55.  
  
 
Acid-fast bacillus smear and culture 
  In HIV-infected patients with pulmonary TB, cultures are positive in 
about 90% of cases and sputum smears are positive in about 50% to 70%--
numbers that are similar to those seen in immunocompetent adults with 
reactivation TB 56.  
Polymerase chain reactions and gene probes are approved for rapid 
identification of M tuberculosis in sputum smears that are positive for acid-fast 
bacilli. These rapid tests are more sensitive than traditional staining methods 
but are not as sensitive as culture. Smears from extrapulmonary sites (e.g., bone 
marrow, lymph nodes) are often negative for acid-fast bacilli. However, the 
sensitivity of culture approaches 90%, depending on the number of samples 
tested 57. 
Bacteriologic Examinations 
  All patients suspected of having pulmonary tuberculosis should have 3 
sputum specimens obtained on 3 consecutive days, and these specimens should 
be examined for AFB and cultured for mycobacteria. AFB identified on smear 
is not diagnostic of tuberculosis, as the acid-fast stain detects mycobacteria 
other than M tuberculosis, including M avium-intracellulare complex or M 
kansasii. However, until identification is confirmed, empiric therapy for 
tuberculosis should be initiated if the sputum smear is positive for AFB. The 
rate of AFB smear positivity has varied from 31% to 89% in HIV-positive 
patients. 58 In general, the rate of smear positivity correlates with the extent of 
radiographic disease. For example, patients with cavitary lesions due to active 
tuberculosis will almost always have positive smears, whereas a negative smear 
in a patient with minimal disease on chest radiograph would not be unusual, and 
would not rule out active tuberculosis. However, in HIV-infected patients 
positive smears may be seen with relatively little radiographic involvement.  
When expectorated sputum specimens are AFB smear-negative, further 
evaluation may be indicated. Bronchoscopy with bronchoalveolar lavage and 
transbronchial biopsy may be useful in the evaluation of an abnormal chest 
radiograph when sputum smears are negative. In this setting, a rapid diagnosis 
of presumptive tuberculosis, based on histology and AFB smear of specimens 
obtained by bronchoscopy, can be made in 30-40% of individuals, which is 
similar to the yield of bronchoscopy in HIV-negative cases with smear-negative 
pulmonary tuberculosis. 59.  
 
        Positive cultures for M tuberculosis provide a definitive diagnosis of 
tuberculosis. Approximately 15% of reported tuberculosis cases are culture 
negative, but these data are not available for HIV-infected cases. However, at 
San Francisco General Hospital, culture-negative tuberculosis in HIV-infected 
patients is seldom observed. (This perceived increase in sensitivity might be 
due in part to the increased use of diagnostic bronchoscopy in HIV-positive 
cases of suspected tuberculosis.) Unfortunately, culture results may not be 
available for 2-6 weeks, creating a need for more rapid diagnostic techniques.  
Nucleic acid amplification (NAA) tests detect nucleic acid sequences 
unique to organisms in the M tuberculosis complex, allowing for a rapid 
diagnosis. Two NAA tests, the Amplified Mycobacterium Tuberculosis Direct 
Test (MTD; Gen-Probe) and the Amplicor Mycobacterium Tuberculosis Test 
(Amplicor; Roche) have been approved by the U.S. Food and Drug 
Administration (FDA) for use in respiratory specimens in patients who have not 
previously been treated for tuberculosis. The MTD test is approved for use in 
smear-positive or smear-negative samples, whereas Amplicor is only approved 
for use with smear-positive samples. 
       A negative NAA test does not rule out the diagnosis of active 
tuberculosis, and antituberculous therapy and further diagnostic workup are 
needed if sufficient clinical suspicion for tuberculosis exists. The predictive 
value of NAA testing will vary depending on the sensitivity and specificity of 
the test in the local laboratory, as well as on the prevalence of M tuberculosis 
and other mycobacteria. Moreover, NAA testing does not provide information 
on drug resistance. NAA tests are an important addition to our armamentarium 
of diagnostic tools, but they do not replace AFB smear, culture, or, more 
importantly, clinical judgment. 
Diagnosis of Latent Tuberculosis Infection 
Screening for latent tuberculosis infection (LTBI) is an essential step in 
controlling the spread of tuberculosis. Screening for LTBI is recommended in 
persons at risk for recent infection and in those groups with increased risk of 
progression to active disease once infected, including HIV-infected persons. 
The tuberculin skin test (Mantoux method) is currently the only method 
available for identifying LTBI. Routine annual tuberculin skin testing is 
recommended in HIV-infected individuals. 
A reaction of >=5 mm induration is considered positive for HIV-infected 
patients and persons with other forms of severe immunosuppression, persons 
who are close contacts of infectious cases, and persons with abnormal chest 
radiographs consistent with tuberculosis.60. Use of the 5-mm cutoff is supported 
by a prospective study in the United States demonstrating that the risk of 
tuberculosis was significantly higher in HIV-infected persons with tuberculin 
skin test reactions >=5 mm of induration than in those who have a reaction <5 
mm.48  
 It is important to keep in mind that a negative tuberculin skin test does 
not exclude infection or active disease. Testing with tuberculin purified protein 
derivative is dependent on the presence of an intact cell-mediated immune 
response. In the setting of HIV infection, reduced cell-mediated immunity can 
lead to decreased delayed-type hypersensitivity (DTH) responsiveness, 
resulting in False-negative skin tests. In a multicenter study in the United 
States, the prevalence of a positive tuberculin skin test (>=5 mm) was shown to 
decrease with decreasing CD4 T-cell counts.61 
       Persons who are at risk for tuberculous infection (e.g., injection drug 
users, individuals who are institutionalized or from high-prevalence regions) 
should have a chest radiograph performed even if the tuberculin skin test is 
negative, particularly if their CD4 T-cell count is low. Annual chest radiographs 
should be considered in this high-risk group.  
 Application of multiple skin test antigens (e.g., Candida, mumps, tetanus 
toxoid, etc.), referred to as anergy testing, has been used to assess cell-mediated 
immune function and to distinguish true-negative from false-negative tuberculin 
skin test results. In 1991, the CDC recommended that anergy testing be 
performed in conjunction with tuberculin skin testing in HIV-infected persons 
based on the premise that anergic HIV-infected individuals at high risk for 
tuberculosis infection would benefit from treatment with INH. 62 In 1997, the 
CDC revised its recommendations and no longer recommends anergy testing 
while screening for M tuberculosis infection in HIV-infected persons. 63 The 
revised recommendation is based on the following points. First, there are no 
standardized guidelines for performing anergy skin testing. The appropriate 
number of control antigens to administer or the appropriate cut-off for 
interpreting a test as positive is not known. Second, the response to skin testing 
with control antigens as well as with tuberculin can vary over time. Several 
studies have demonstrated that HIV-1-seropositive individuals can regain DTH 
responsiveness with time. 64, 65, 66 In a multicenter study, Chin and colleagues66 
reported that 31% of anergic HIV-1-seropositive patients responded to DTH 
testing 1 year later. The only factor associated with regaining DTH 
responsiveness was the CD4 T-cell count: the higher the CD4 count, the more 
likely the individual was to regain DTH responsiveness. Finally, treatment of 
LTBI in anergic HIV-infected persons has not been demonstrated to be 
beneficial.67, 68  
In some individuals with tuberculous infection, DTH responsiveness may 
decrease with time. A second tuberculin skin test, applied weeks to months after 
the first, can "boost" the DTH response resulting in a positive skin test reaction. 
Such responses are considered true evidence of tuberculous infection. In a 
multicenter study in the United States, only 2.7% of HIV-1-seropositive 
patients "boosted" the tuberculin reaction with a second tuberculin skin test, 
despite relatively high demographic risk of tuberculous infection.69 However, a 
study in Uganda found that 17 (29%) of 58 HIV-1-infected subjects responded 
to a second tuberculin skin test.70  
Natural history  
Although the immune response to M tuberculosis is important in 
controlling disease, immune activation may also be associated with increased 
HIV viral load and accelerated progression of HIV infection. A retrospective 
cohort study in the United States found that although only one patient in the 
group died of tuberculosis, HIV-infected patients with tuberculosis do not 
survive as long as HIV-infected controls without tuberculosis, even after 
controlling for baseline CD4 T-cell count. When tuberculin-positive HIV-
infected patients were given INH therapy in Haiti, they were less likely to 
develop AIDS and less likely to die than patients given placebo. 71 Thus, it is 
likely that tuberculosis acts to accelerate the clinical course of HIV infection. 
Although increased viral replication is thought to play a role, the 
mechanisms by which tuberculosis accelerates progression of HIV disease are 
not known with certainty. High levels of tumor necrosis factor (TNF)-alpha, 
which are known to increase HIV replication in T-cell clones,72 have been 
demonstrated in both HIV-1-seropositive and -seronegative tuberculosis 
cases.73. 
 Moreover, Investigators have shown that M tuberculosis or purified 
protein derivative can also increase viral replication in infected T lymphocytes 
and monocytes.74-76A recent study demonstrated a 5- to 160-fold increase in 
viral replication during the acute phase of untreated tuberculosis.72 The clinical 
significance of this increase in viral load is uncertain. 
TREATMENT  
STANDARD TREATMENT REGIMENS  
Anti-TB therapy is equally effective in HIV-negative and HIV-positive 
patients. The weight of the evidence to date indicates that the rate of TB relapse 
after short-course (6-month rifamycin-based) therapy is similar for HIV-positive 
and HIV-negative patients, although this remains somewhat controversial.77,78. 
In general, then, the same treatment regimen may be used regardless of HIV 
status. The American Thoracic Society TB treatment guidelines (currently under 
revision) will likely include a recommendation to extend the duration of therapy 
to 9 months (regardless of HIV status) in persons who have both cavitary 
pulmonary disease on initial presentation and positive-sputum cultures after 2 
months of treatment. These changes are based on results of a recent TB-
treatment study conducted by the CDC, in which HIV-negative adults with 
pulmonary disease who met these criteria had a relapse rate of >20% -- far 
higher than the clinically acceptable relapse rate of <5%.79 
In TB-endemic areas, recurrent TB after completion of a course of 
therapy is more likely to be due to exogenous reinfection than to relapse.80. 
Compared with HIV-negative TB patients, co infected patients have a higher 
risk for recurrent TB, but this is due to reinfection rather than relapse.81 In a 
study conducted in Haiti, HIV-infected persons who completed a course of TB 
therapy were less likely to develop recurrent TB if they received a 12-month 
post-treatment course of isoniazid, compared with persons who received 
placebo.82 However, such practice has been implemented neither in developing 
countries (due to insufficient infrastructure) nor in developed countries (due to 
lower TB incidence rates and lower rates of exogenous reinfection).  
 
PHARMACOKINETIC INTERACTIONS  
A central aspect of TB treatment in HIV-infected patients is the 
pharmacokinetic interactions between rifamycins (e.g., rifampin and rifabutin) 
and PIs and NNRTIs. Although these interactions do not preclude the 
concomitant use of potent antiretroviral therapy and anti-TB therapy, clinicians 
must be aware of these interactions and adjust dosages accordingly. Although 
large studies of the effectiveness of rifabutin-based regimens in co infected 
patients concomitantly receiving antiretroviral therapy are underway, the results 
will not be available for 1 to 2 years. However, 2 small studies have 
demonstrated that rifabutin-based regimens are well tolerated and effective in 
such patients.83, 84  
DIRECTLY OBSERVED THERAPY  
Self-administered TB therapy has been compared with directly observed 
therapy in very few well designed, randomized, controlled studies; however, the 
available data indicate that directly observed therapy is associated with 
decreased rates of TB incidence and drug resistance85 and increased rates of 
sputum conversion and therapy completion.86 Among HIV-infected patients, 
directly observed therapy has been associated with improved survival.87 Because 
of these benefits, directly observed TB therapy is recommended by the 
American Thoracic Society, the CDC, and the WHO.88, 89  
The regimen of DOTS is as shown below: 
 
Category of  
Treatment 
Type of patient Regimen Sputum 
Examination        
CAT-I New sputum smear 
positive 
Seriously ill sputum-
negative 
Seriously -ill-EP
2 H3R3Z3E3/ 
4 H3R3 
0  2  4    6 
      3    5    7 
MONTHS 
CAT- II Sputum smear +  
Relapse, Failure 
,Treatment after 
Default  
3 H3R3Z3E3S3/ 
1 H3R3Z3E3/ 
5 H3R3E3. 
0  3   5    8 
      4    6      9 
CAT-III Sputum negative not 
seriously ill ,EP not 
seriously ill 
2 H3R3Z3/ 
4 H3R3 
0     2      6 
 
Abbreviations: 
H- INH, R- Rifampicin, Z- Pyrazinamide, E- Ethambutol, S-Streptomycin. 
 
 
 
 
HIV AND PARADOXICAL WORSENING OF TB  
Paradoxical worsening of TB is the development of new signs or symptoms of 
TB disease or the exacerbation of existing manifestations of TB in patients 
receiving appropriate anti-TB therapy. Diagnosis of paradoxical worsening 
requires that other possible explanations be excluded, such as treatment failure, 
drug resistance, poor compliance, malabsorption, adverse drug reactions, and 
lymphoma. Paradoxical worsening is thought to represent an improvement of 
the host's immune response to mycobacterial antigens during the course of 
treatment, leading to more intense inflammation at sites of TB disease.  
The estimated incidence of paradoxical worsening of TB in HIV-infected 
patients ranges from 7% to 36%, which is higher than the rate seen in HIV-
negative patients. In one hospital-based study, higher rates of paradoxical 
worsening in co infected patients were associated with the use of antiretroviral 
therapy.90 In a retrospective study of HIV-infected patients receiving outpatient 
TB treatment, the incidence of paradoxical worsening was not associated with 
the use of potent combination antiretroviral therapy, but patients experiencing 
paradoxical worsening while on antiretroviral therapy had a more severe and 
prolonged course. Paradoxical worsening of TB in HIV-infected patients has 
been associated with the presence of concurrent pulmonary and extrapulmonary 
TB at the time of initial diagnosis.91 
The course of paradoxical worsening can be brief or prolonged, with multiple 
recurrences and exacerbations. Corticosteroid treatment of severe episodes of 
paradoxical worsening has not been associated with progression of TB disease 
or failure of anti-TB therapy. Patients with less severe symptoms may obtain 
relief with nonsteroidal anti-inflammatory medications. Although antiretroviral 
therapy may be associated with the development or severity of paradoxical 
worsening, discontinuation of therapy is not generally recommended. 
TREATMENT OF LATENT TB INFECTION  
As noted above, the risk for progressing to active TB is high among HIV-
seropositive persons infected with M. tuberculosis. Therefore, all HIV-infected 
persons with evidence of latent M. tuberculosis infection should receive 
treatment. See Table 1 for the indications for treatment of latent infection in 
HIV-infected persons and potential treatment regimens. In a study among HIV-
infected persons with latent M. tuberculosis infection, 2 months of daily 
rifampin + pyrazinamide was as effective as 12 months of daily isoniazid in 
preventing active TB; both regimens were well tolerated.92 A recent study found 
that combination short-course regimens had a more durable protective effect 
than did isoniazid alone.93. However, there have recently been 6 hepatotoxicity-
associated deaths reported among persons taking daily rifampin + 
pyrazinamide.94, 95 Although none of the 6 persons was HIV-positive, the 
recommendations for the treatment of latent TB infection have been revised to 
state that this regimen should not be offered to patients with underlying liver 
disease or with prior isoniazid-associated hepatotoxicity. This regimen should 
be used with particular caution in patients concurrently taking other medications 
associated with liver injury and in those with a history of alcohol abuse. See 
Table 1 for recommendations for toxicity monitoring during treatment for latent 
TB infection.  
The WHO recommends treating latent M. tuberculosis infection in HIV-infected 
persons in the developing world. However, implementation of this policy has 
been incomplete due to limited resources in these settings. This is particularly 
true in settings in which resources are insufficient to identify and treat all 
persons with active TB, which remains a higher priority.    
 
 
 
 
 
WHO recommendations for the treatment of TB and HIV co infection with 
reference to CD-4 cell count. 
CD 4 cell count Recommended 
regimen  
Comments 
< 200 mm3 Start TB treatment. Start 
ART as soon as TB 
treatment is tolerated (2 
weeks to 2 months) 
EFV containing 
regimens. 
Recommended ART 
EFV is contraindicated in 
pregnant or women of 
childbearing potential 
without effective 
contraception 
200 to 350 mm3 Start TB treatment. start 
one of the below 
regimens after initiation 
phase: EFV containing 
regimens or NVP 
containing regimens in 
case of Rifampicin free 
continuation phase TB 
treatment regimen. 
Consider ART 
> 350 mm3 
 
Start TB treatment. 
 
Defer ART 
 
CD 4 count not available 
 
Start TB treatment. Consider ART 
 
 
Abbreviations: 
EFV- efavirenz, NVP – nevirapine. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
Methodology 
Persons who reported having high-risk factors for the HIV infection 
were screened for HIV status at the Voluntary Counseling and Testing 
Center at both Thanjavur Medical College and The Raja Mirasudar 
Hospital, attached to the Thanjavur Medical College, from April 2005 
to March 2006.    
 
Screening of HIV infection was done by ELISA rapid diagnostic tests, 
1. Immunoblot,  
2. Combaids and 
3. Tridot Methods. 
Patients who were positive in at least two of these three tests were 
considered positive for HIV infection. 
 
A brief History of illness was taken from the seropositive individuals and 
these patients were subjected to the following further investigations that 
include, 
 
Blood Hemoglobin, 
Total count, 
Differential count, 
Erythrocyte Sedimentation Rate, 
Liver Function Test, 
Sputum Microscopic Examination for Acid Fast Bacilli, 
Chest X-Ray PA view, 
Mantoux test and  
CD-4+ cell count. 
 
Blood Hemoglobin, Total count, Differential count, ESR were all done using 
the conventional Laboratory methods. 
Sputum Examination: Two spot and one early morning sputum samples 
were examined for Acid Fast Bacilli (AFB) positivity using the Ziehl-
Nielsen technique.   
CD –4 + cell count was done using FACS Analyzer.  
Patients were considered to be suffering from Tuberculosis if,  
1. Sputum is positive for AFB. 
2. The Mantoux test reading shows induration above 5mm. 
3. X-Ray features were suggestive of Tuberculosis. Since there is a high 
reporting of both inter-observer and intra-observer variations, 
opinions were obtained from three persons separately – a general 
physician, a thoracic physician and a radiologist and their 
Tuberculosis status confirmed. 
 
INCLUSION CRITERIA: 
 
Patients, who are found seropositive with stigmata for tuberculosis like 
fever, cough with expectoration lasting for more than three weeks, loss of 
appetite and loss of weight. 
Patients with Tuberculous Pleural Effusion were included in the study. 
 
EXCLUSION CRITERIA: 
 
1. Patients who are suffering from Extra-pulmonary Tuberculosis 
infections like TB Pericarditis, TB meningitis, TB Abdomen, isolated 
TB lymphadenopathy, Potts Spine and other seriously ill patients. 
2. Patients found to have positivity in only one of the three ELISA tests. 
3. No consensus among all the three independent observers regarding the 
X-Ray features of Tuberculosis infection. 
 
STUDY LIMITATIONS: 
 
The confirmation of HIV infection could not be done by Western Blot 
analysis. 
The sputum positivity for tuberculosis infection in HIV infected 
individuals is low when compared with sero-negative individuals. Hence, 
for confirmation of Tuberculosis infection in these seropoitive 
individuals, sputum culture must be done which could not be done in our 
study.    
 
   
   
 
 
    
TUBERCULOSIS: an overview 
Tuberculosis has been present in humans since antiquity, as the origins of the 
disease are in the first domestication of cattle (which also gave humanity viral 
poxes). Skeletal remains show prehistoric humans (4000 BC) had TB and 
tubercular decay has been found in the spines of Egyptian mummies from 3000-
2400 BC. There were references to TB in India around 2000 BC, and 
indications of lung scarring identical to that of modern-day TB sufferers in 
preserved bodies (such as mummies) suggests that TB was present in The 
Americas from about 2000 BC 
Phthisis is a Greek term for consumption. Around 460 BC, Hippocrates 
identified phthisis as the most widespread disease of the times which was 
almost always fatal. 
Due to the variety of its symptoms, TB was not identified as a single disease 
until the 1820s and was not named 'tuberculosis' until 1839 by J. L. Schönlein. 
The bacillus-causing tuberculosis, Mycobacterium tuberculosis, was identified 
and described on March 24, 1882 by Robert Koch. He received the Nobel Prize 
in physiology or medicine in 1905 for this discovery. 
 
The other names for tuberculosis are: 
TB (short for tuberculosis and also for Tubercle Bacillus)  
Consumption (TB seemed to consume people from within with its 
symptoms of bloody cough, fever, pallor, and long relentless wasting)  
Wasting disease   
White plague (TB sufferers appear markedly pale)  
Phthisis (Greek for consumption) and phthisis pulmonalis  
 King's evil   
Miliary TB (x-ray lesions look like millet seeds)  
 Koch's Disease named after Robert Koch who discovered the tuberculosis 
bacilli. 
Pathogenesis 
While only 10% of TB infection progresses to TB disease, if untreated the death 
rate is 51%. 
TB infection begins when MTB bacilli reach the pulmonary alveoli, infecting 
alveolar macrophages, where the mycobacteria replicate exponentially. The 
primary site of infection in the lungs is called the Ghon focus. Bacteria are 
picked up by dendritic cells, which can transport the bacilli to local 
(mediastinal) lymph nodes, and then through the bloodstream to the more 
distant tissues and organs where TB disease could potentially develop: lung 
apices, peripheral lymph nodes, kidneys, brain, and bone. 
Tuberculosis is classed as one of the granulomatous inflammatory conditions. 
Macrophages, T lymphocytes, B lymphocytes and fibroblasts are among the 
cells that aggregate to form a granuloma, with lymphocytes surrounding 
infected macrophages. The granuloma functions not only to prevent 
dissemination of the mycobacteria, but also provides a local environment for 
communication of cells of the immune system. Within the granuloma, T 
lymphocytes (CD4+) secrete a cytokine such as interferon gamma, which 
activates macrophages to destroy the bacteria with which they are infected, 
making them better able to fight infection. T lymphocytes (CD8+) can also 
directly kill infected cells. 
Importantly, bacteria are not eliminated with the granuloma, but can become 
dormant, resulting in a latent infection. Latent infection can be diagnosed only 
by tuberculin skin test, which yields a delayed hypersensitivity type response to 
purified protein derivatives of M. tuberculosis in an infected person. 
Another feature of the granulomas of human tuberculosis is the development of 
cell death, also called necrosis, in the center of tubercles. To the naked eye this 
has the texture of soft white cheese and was termed caseous necrosis. 
If TB bacteria gain entry to the blood stream from an area of tissue damage they 
spread through the body and set up myriad foci of infection, all appearing as 
tiny white tubercles in the tissues. This is called miliary tuberculosis and has a 
high case fatality. 
Progression 
In those people in whom TB bacilli overcome the immune system defenses and 
begin to multiply, there is progression from TB infection to TB disease. This 
may occur soon after infection (primary TB disease – 1 to 5%) or many years 
after infection (post primary TB, secondary TB, reactivation TB disease of 
dormant bacilli – 5 to 9%). 
About five percent of infected persons will develop TB disease in the first two 
years, and another five percent will develop disease later in life. In other words, 
about 10% of infected persons with normal immune systems will develop TB 
disease in their lifetime. 
Some medical conditions increase the risk of progression to TB disease. In HIV 
infected persons with TB infection, the risk increases to 10% each year instead 
of 10% over a lifetime. Other such conditions include drug injection (mainly 
because of the life style of IV Drug users), substance abuse, recent TB infection 
(within two years) or history of inadequately treated TB, chest X-ray suggestive 
of previous TB (fibrotic lesions and nodules), diabetes mellitus, silicosis, 
prolonged corticosteroid therapy and other immunosuppressive therapy, head 
and neck cancers, hematologic and reticuloendothelial diseases (leukemia and 
Hodgkin's disease), end-stage renal disease, intestinal bypass or gastrectomy, 
chronic malabsorption syndromes, or low body weight (10% or more below the 
ideal). 
TB disease most commonly affects the lungs (75% or more), where it is called 
pulmonary TB. Symptoms include a productive, prolonged cough of more than 
three weeks duration, chest pain, and hemoptysis. Systemic symptoms include 
fever, chills, night sweats, appetite loss, weight loss, and easy fatigability.  
Diagnosis 
A complete medical evaluation for TB includes a medical history, a physical 
examination, a tuberculin skin test, a serological test, a chest X-ray, and 
microbiologic smears and cultures. Bacteriophage-based assays are among a 
few new testing procedures that offer the hope of cheap, fast and accurate TB 
testing for the impoverished countries that need it most. 
HIV – an introduction.1 
In 1981, the first cluster of cases that we now call AIDS was recognized and 
reported. Nearly all of the early identified cases were in young homosexual 
men, but it was quickly learned that HIV infection could be transmitted by 
heterosexual contact and by blood transfer from infected to non infected 
individuals. 
 
The clinical consequences of human immunodeficiency virus (HIV) infection 
are due to the ability of this virus to disarm the host immune system, a process 
that occurs by virtue of the fact that the primary target for the virus is the 
helper-inducer subset of lymphocytes. This lymphocyte subset, defined by its 
surface expression of the CD4 molecule, acts as the pivotal orchestrator of a 
myriad of immune functions. HIV infection can therefore be considered a 
disease of the immune system, characterized by the progressive loss of CD4-
positive (CD4+) lymphocytes, with ultimately fatal consequences for the 
infected host. 
 
Despite this immunosuppression induced by HIV, a number of specific 
immunologic defenses against the virus are generated in infected individuals 
and may contribute to the long asymptomatic phase following infection by 
keeping the virus at least partially contained. 
The hallmark of HIV infection is progressive depletion of the CD4 helper-
inducer subset of lymphocytes. Because of the central role of these cells in 
immunologic functioning, the clinical disease manifestations of 
immunosuppression and susceptibility to opportunistic infections and 
neoplasms are not surprising. The immunologic deficits associated with HIV 
infection are widespread and involve numerous interdependent effector arms of 
the immune system, including both cellular and humoral elements. 
 
Of all the opportunistic infections in persons infected with HIV virus 
tuberculosis remains the commonest. 
 
HIV probably increases susceptibility to infection with M. tuberculosis. 
HIV increases the risk of progression of M. tuberculosis infection to TB 
disease. This risk increases with increasing immunosuppression. HIV 
increases not only the risk but also the rate of progression of recent or 
latent M. tuberculosis infection to disease. 
 
 
 
 
 
  
 
 
 
 
Shown above is the diagram of the Human immunodeficiency virus showing 
the envelope glycoprotein and reverse transcriptase enzyme.  
 
WHO clinical staging system for HIV infection and related 
disease in adults (13 years or older)2 
Stage 1:  º Asymptomatic 
º Persistent generalized lymphadenopathy 
Performance scale 1: asymptomatic, normal activity 
Stage 2:       º Weight loss < 10% of body weight 
º Minor mucocutaneous manifestations 
(e.g. oral ulcerations, fungal nail infections) 
º Herpes zoster within the last 5 years 
º Recurrent upper respiratory tract infections 
(e.g. bacterial sinusitis) 
and/or Performance scale 2: symptomatic, normal activity 
Stage 3:  º Weight loss > 10% of body weight 
º Unexplained chronic diarrhoea for more than 1 month 
º Unexplained prolonged fever for more than 1 month 
º Oral candidiasis (thrush) 
º Oral hairy leukoplakia 
º Pulmonary TB 
º Severe bacterial infections (pneumonia, pyomyositis) 
and/or Performance scale 3: bedridden < 50% of the day 
during the last month 
Stage 4: º HIV wasting syndrome. 
º Pneumocystis carinii pneumonia 
º Toxoplasmosis of the brain 
º Cryptosporidiosis with diarrhoea, for more than 1 month 
º Cryptococcosis, extrapulmonary 
º Cytomegalovirus (CMV) disease of an organ other than 
liver, spleen, lymph nodes 
º Herpesvirus infection, mucocutaneous for more than 1 
month, or visceral any duration 
º Progressive multifocal leukoencephalopathy (PML) 
º Any disseminated endemic fungal infection 
(e.g. histoplasmosis) 
 
WHO case definitions for AIDS surveillance in adults and children 
where HIV testing facilities are not available 
Adults 
The case definition for AIDS is fulfilled if at least 2 major signs and at 
least 1 minor sign are present. 
Major signs 
º Weight loss > 10% of body weight 
º Chronic diarrhoea for more than 1 month 
º prolonged fever for more than 1 month 
Minor signs 
º Persistent cough for more than 1 month 
º generalized pruritic dermatitis 
º History of herpes zoster 
º oropharyngeal candidiasis 
º Chronic progressive or disseminated herpes simplex infection 
º generalized lymphadenopathy 
The presence of either generalized Kaposi sarcoma or cryptococcal 
meningitis is sufficient for the case definition of AIDS. 
The advantages of this case definition are that it is simple to use and 
inexpensive. The disadvantages are its relatively low sensitivity and 
specificity. For example, HIV-negative TB cases could be counted as AIDS 
cases because of their similarity in clinical presentation. 
PRACTICAL POINT 
The term AIDS is used for epidemiological surveillance, not 
for clinical care.  a for patients with TB, persistent cough for more than 1 
month should not be considered as a minor sign. 
 RISK OF HIV IN TB PATIENTS 
 
 
 
 
 
 
 
 HIV AND TB COINFECTION IN SOUTH INDIA. 
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Picture showing estimated HIV and TB co infection in India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FEATURES AND CLINICAL PRESENTATION IN RELATION TO STAGE OF HIV 
INFECTION 
TB 20 Million 
HIV 
4 Million 
 
?Atypical presentation, often 
infiltrates 
?Lower lung-field lesions, 
intra-thoracic lymph nodes & 
infrequent cavities 
Often shows 
cavities 
Chest X-ray 
Appearance 
Often negative Often positive Sputum Smear 
Result 
Often resembles Primary TB 
Extra pulmonary TB common 
Often resembles 
Post-primary TB 
(Adult-type) 
Clinical 
Presentation  
Late Early 
Stage of HIV infection  
Features 
HIV AND 
TB 2 million 
 Tuberculosis in HIV infection: 
HIV has had a substantial effect on the incidence, clinical manifestations, 
treatment, and outcome of TB. Globally, HIV and TB are the 2 leading 
infectious causes of death. 
People who are infected with HIV are at an increased risk of contracting 
tuberculosis. The WHO estimates that just over 20 million people are currently 
infected with HIV and of these 6 million are co-infected with Mycobacterium 
tuberculosis so Tuberculosis remains an important problem in patients with 
human immunodeficiency virus (HIV) infection. 
Co infection with these pathogens can be particularly devastating, 
especially in the developing world, where the burden of disease is high and 
access to effective therapy is low. 
Among infections associated with HIV, tuberculosis (TB) is unique in 
that it may be transmitted to immunocompetent persons via the respiratory 
route, is easily treatable once identified, may occur in early-stage HIV disease, 
and is preventable with drug therapy.  
However, multi drug resistance is a potentially serious problem, even though its 
incidence has declined because of the use of directly observed therapy and other 
improved practices. 
 
TB is a major opportunistic infection in HIV-infected patients, often 
representing their AIDS-defining illness and the first indication of 
immunodeficiency. Epidemiology, clinical manifestations, and management of 
TB are altered in HIV-infected patients. 
Impact of HIV on TB 
HIV is the most significant risk factor for progression from sub clinical 
infection with Mycobacterium tuberculosis to active TB 3,4.  
However, when a person is dually infected with HIV and M. tuberculosis, 
the risk of developing TB significantly increases from 10% in a life time to 
5%–15% per year5 -8. HIV-infected persons are at markedly increased risk for 
primary or reactivation tuberculosis9, 10 and for second episodes of tuberculosis 
from exogenous reinfection.11 The lifetime risk for progressing to active TB 
among HIV-negative persons latently infected with M. tuberculosis is estimated 
at 10%. In contrast, among HIV-infected persons, the risk for progressing to 
active disease is approximately 10% per year, 12 and the immediate risk for 
progressive primary disease after recent infection with M. tuberculosis 
approaches 40%.13 This interaction between TB and HIV accounts for much of 
the recent global resurgence in TB. Of note, however, HIV infection does not 
increase the infectiousness of persons with active TB.14 The introduction of 
potent combination antiretroviral therapy in the developed world, which has 
dramatically decreased the risk for opportunistic infections and death among 
HIV-infected persons, has also decreased the risk for developing active TB15 
and the risk for death among HIV-infected persons who develop active TB16. 
 
   
Epidemiology  
The frequency with which HIV and Mycobacterium tuberculosis 
infection occur together is determined by the epidemiology of each disease in a 
given population. Highest rates are found in the homeless, injecting drug users, 
and recent immigrants and refugees17. 
The incidence of TB in HIV-infected persons is more than 100 times that 
of the general population. In untreated HIV-infected persons who have a 
positive tuberculin skin test, the risk of active TB is about 8% per year 18. 
Nosocomial transmission of TB from HIV-infected patients to 
healthcare workers has been reported 19. 
One of the most threatening features of TB in HIV-infected patients has 
been the spread of multi drug-resistant (MDR) organisms 20. MDR TB is 
defined as disease that is resistant to at least two drugs (INH and Rifampicin). 
Its incidence has declined dramatically in recent years with more rapid case 
identification, improved isolation practices, use of early empirical therapy with 
drugs directed against MDR strains 21, and use of directly observed therapy 22 
Pathogenesis  
Tuberculosis can develop through progression of recently acquired 
infection (primary disease), reactivation of latent infection, or exogenous 
reinfection. 
Infection with M tuberculosis can occur when an individual exposed to 
an infectious case of tuberculosis inhales particles (<5 µm in size) containing 
the tubercle bacilli.23 If the bacilli reach the pulmonary alveoli, they may be 
ingested by alveolar macrophages, the first line of defense against M 
tuberculosis. Surviving tubercle bacilli multiply within the macrophage and 
eventually undergo hematogenous spread to other areas of the body. 
Once infection does occur, however, the risk of rapid progression is 
much greater among persons with HIV infection, because HIV impairs the 
host's ability to contain new tuberculous infection. 
       Immunocompetent individuals infected with M tuberculosis have 
approximately a 10% lifetime risk of developing tuberculosis, 24 with half of the 
risk occurring in the first 1-2 years after infection. 
 CD4 cell-mediated immunity and macrophage function are essential in 
the control of M tuberculosis infection. During primary infection of an 
immunocompetent host, cell-mediated immunity usually develops and arrests 
progression of disease. About 5% of patients whose primary infection is 
controlled have reactivation years to decades later. In another 5% of patients, 
infection is not contained, and primary pulmonary, extra pulmonary or 
disseminated TB can occur.  
Susceptibility to tuberculosis is related to the pattern of cytokines produced by 
T lymphocytes. CD4+ lymphocytes, which produce interferon- , are central to 
antimycobacterial immune defenses, and fatal mycobacterial disease develops 
in children who lack the interferon-  receptor.25 In contrast to CD4+ 
lymphocytes, CD8+ lymphocytes, which produce interleukin-4 and interleukin-
10, do not contribute to antimycobacterial immunity.26 When peripheral-blood 
lymphocytes from HIV-infected patients with tuberculosis are exposed to 
Mycobacterium tuberculosis in vitro, they produce less interferon-  but similar 
amounts of interleukin-4 and interleukin-10, as compared with lymphocytes 
from HIV-negative patients with tuberculosis.27 These findings suggest that the 
reduced CD4+ response in HIV-infected patients contributes to their 
susceptibility to tuberculosis.  
The hallmark of HIV infection is progressive deterioration and depletion 
of CD4 cells, coupled with defects in macrophage and monocyte function 28. 
There is evidence that the immune response in patients with TB might enhance 
HIV viral replication and accelerate the natural progression of HIV infection 29. 
The risk of TB developing in an HIV-infected patient who is latently co-
infected with M tuberculosis approaches 10% per year, as opposed to a 10% 
lifetime risk in an immunocompetent host 30. Patients with more advanced HIV 
infection (CD4   count, <200 cells/mm3) who are newly infected with 
M.tuberculosis may lack the ability to contain the primary infection, which can 
progress rapidly and is fatal if not treated. Infection with M tuberculosis in an 
immunocompetent person is thought to confer significant protective immunity 
against exogenous reinfection.24 However, reinfection has been reported in 
HIV-seronegative31,32 and -seropositive individuals,33-37 although its incidence is 
not known 
Tuberculosis and the Course of HIV Infection  
Exposure of alveolar macrophages and lymphocytes from HIV-infected patients 
to M. tuberculosis in vitro up-regulates retroviral replication.38,39  
TB has been associated with a 5- to 160-fold increase in HIV viral replication, 
which may decrease after successful TB treatment.40  
 Pleural fluid from patients with tuberculosis increases HIV replication in 
activated lymphocytes,41 and in HIV-infected patients with pulmonary 
tuberculosis, the concentrations of retroviral RNA in bronchoalveolar-lavage 
fluid are highest in areas of tuberculous involvement.42 M. tuberculosis 
probably increases HIV replication by inducing macrophages to produce tumor 
necrosis factor , interleukin-1, and interleukin-6.41,42  
Clinical studies have shown the detrimental effects of tuberculosis on the 
course of HIV infection. The risk of death in HIV-infected patients with 
tuberculosis was reported to be twice that in HIV-infected patients without 
tuberculosis, independently of the CD4 cell count.43 The high mortality rate 
among patients with tuberculosis appeared to be due to progressive HIV 
infection rather than tuberculosis. The degree of immunosuppression is the most 
important predictor of survival in HIV-infected patients with tuberculosis, since 
negative tuberculin skin tests, prior opportunistic infections, and low CD4 cell 
counts are associated with increased mortality.44,45 
Clinical presentation  
 Unlike other opportunistic infections, TB can occur in persons with 
early-stage HIV infection (CD4 count, >300 cells/mm3). Clinical presentation 
of TB in such patients is similar to that in healthy hosts with reactivation 
disease 46. Patients are less likely to present with extrapulmonary disease at this 
stage of HIV infection. Because of the increased virulence in immunocompetent 
hosts of M tuberculosis compared with other opportunistic pathogens (e.g., 
Pneumocystis jiroveci), tuberculosis can occur early in the course of HIV 
infection. In several studies of HIV-infected patients with pulmonary 
tuberculosis, the median CD4 T-cell count was >300 cells/mm3. (38) However, 
in patients with primarily extrapulmonary involvement or disseminated disease, 
the CD4 T-cell count may be much lower. For example, two studies in African 
patients with disseminated disease found the median CD4 T-cell count to be 
<80 cells/mm3.47 A prospective study in the United States,48 found the  median 
CD4 T-cell count to be 144 cells/mm3 (range 2-543) in HIV-infected patients 
with all forms 
 of tuberculosis. Although tuberculosis can be a relatively early manifestation of 
HIV-1 infection, it is important to note that the risk of developing tuberculosis, 
and of disseminated infection, increases as the CD4 T-cell count decreases. 
   Typical symptoms include fever, weight loss, productive cough of 
several weeks' duration, and hemoptysis. Chest radiographs demonstrate the 
presence of focal infiltrates and/or cavitation involving the upper lobes.  
 In patients with advanced HIV disease, TB may present atypically and 
extrapulmonary TB is more common. Disseminated disease with involvement 
of bone marrow, bone, urinary and gastrointestinal tracts, liver, regional lymph 
nodes, and the central nervous system is common 30, 46.  
Radiographic Findings 
 The chest radiograph is the cornerstone of diagnosis for pulmonary 
tuberculosis. Upper lobe infiltrates and cavities are the typical findings in 
reactivation tuberculosis, whereas intrathoracic lymphadenopathy and lower 
lobe disease are seen in primary tuberculosis. In HIV-infected persons with 
higher CD4 T-cell counts (e.g., >200 cells/mm3) the radiographic pattern tends 
to be one of reactivation disease with upper lobe infiltrates with or without 
cavities. 49 In HIV-infected persons who have a greater degree of 
immunosuppression (e.g., CD4 T-cell count <200 cells/mm3), a pattern of 
primary disease with intrathoracic lymphadenopathy and lower lobe infiltrates 
is seen (Figure 2 and Figure 3). As chest radiographs may appear normal in 7-
14% of cases, a high index of suspicion must be maintained in evaluating an 
HIV-infected patient with symptoms suggestive of tuberculosis. 50,51 .The 
finding of low-density lymph nodes with peripheral enhancement on a contrast-
enhanced chest computed tomography (CT) scan is highly predictive of 
tuberculosis. 
Chest radiographs may be normal or show evidence of perihilar or 
mediastinal lymphadenopathy without parenchymal lung involvement. 
Radiographs and   clinical presentation may mimic community-acquired 
pneumonia or Pneumocystis carinii pneumonia. Cavitation is unusual at this 
stage of advanced immunosuppression, and infiltrates more often are diffuse or 
interstitial.  Mycobacterial blood cultures may yield M tuberculosis in one third 
of patients with advanced HIV immunosuppression 52 a severely 
immunocompromised person presenting with TB may not show cavitation and 
may have only mild interstitial infiltrates. Pneumonia, lung tumors, and fungal 
masses may also occur at the site of previously healed TB or granulomatous 
lesions. 
Testing for HIV Infection in Patients with Tuberculosis  
All patients with tuberculosis should be tested for HIV co infection because of 
the potential benefits of an early diagnosis of HIV infection.53  
Selective HIV testing in patients with tuberculosis is unwise, because health 
care providers often fail to identify risk factors for HIV related to heterosexual 
transmission.54 Even when patients with tuberculosis are questioned about risk 
factors for HIV infection, up to 5 percent of those who report no risk factors are 
infected with HIV.54 
 
 
Diagnosis  
 In patients with TB and HIV infection, special consideration is required 
in assessing results of tuberculin skin test and acid-fast bacillus smear and 
culture.  
Tuberculin skin test 
           HIV infection causes depression of cell-mediated immunity, which can 
reduce the sensitivity and reliability of the tuberculin skin test. Only 30% to 
50% of HIV-infected patients who are co infected with M tuberculosis have a 
positive result on the tuberculin skin test 46. Although a positive result increases 
the likelihood of TB, a negative result does not exclude the diagnosis.  
 
Therefore, diagnostic evaluation for TB should be undertaken in all 
patients who have clinical features compatible with TB, regardless of the results 
of the tuberculin skin test. Several cohort studies have demonstrated a high 
incidence of active tuberculosis among HIV-infected individuals with positive 
tuberculin skin test results.   
 There are recent reports of restoration of delayed hypersensitivity on 
skin testing, including tuberculin skin testing in HIV-infected patients who 
begin highly active antiretroviral therapy. This reaction reflects restoration of 
the anti-M tuberculosis cell-mediated immune response, a phenomenon that 
usually occurs within the first month of therapy 55.  
  
 
Acid-fast bacillus smear and culture 
  In HIV-infected patients with pulmonary TB, cultures are positive in 
about 90% of cases and sputum smears are positive in about 50% to 70%--
numbers that are similar to those seen in immunocompetent adults with 
reactivation TB 56.  
Polymerase chain reactions and gene probes are approved for rapid 
identification of M tuberculosis in sputum smears that are positive for acid-fast 
bacilli. These rapid tests are more sensitive than traditional staining methods 
but are not as sensitive as culture. Smears from extrapulmonary sites (e.g., bone 
marrow, lymph nodes) are often negative for acid-fast bacilli. However, the 
sensitivity of culture approaches 90%, depending on the number of samples 
tested 57. 
Bacteriologic Examinations 
  All patients suspected of having pulmonary tuberculosis should have 3 
sputum specimens obtained on 3 consecutive days, and these specimens should 
be examined for AFB and cultured for mycobacteria. AFB identified on smear 
is not diagnostic of tuberculosis, as the acid-fast stain detects mycobacteria 
other than M tuberculosis, including M avium-intracellulare complex or M 
kansasii. However, until identification is confirmed, empiric therapy for 
tuberculosis should be initiated if the sputum smear is positive for AFB. The 
rate of AFB smear positivity has varied from 31% to 89% in HIV-positive 
patients. 58 In general, the rate of smear positivity correlates with the extent of 
radiographic disease. For example, patients with cavitary lesions due to active 
tuberculosis will almost always have positive smears, whereas a negative smear 
in a patient with minimal disease on chest radiograph would not be unusual, and 
would not rule out active tuberculosis. However, in HIV-infected patients 
positive smears may be seen with relatively little radiographic involvement.  
When expectorated sputum specimens are AFB smear-negative, further 
evaluation may be indicated. Bronchoscopy with bronchoalveolar lavage and 
transbronchial biopsy may be useful in the evaluation of an abnormal chest 
radiograph when sputum smears are negative. In this setting, a rapid diagnosis 
of presumptive tuberculosis, based on histology and AFB smear of specimens 
obtained by bronchoscopy, can be made in 30-40% of individuals, which is 
similar to the yield of bronchoscopy in HIV-negative cases with smear-negative 
pulmonary tuberculosis. 59.  
 
        Positive cultures for M tuberculosis provide a definitive diagnosis of 
tuberculosis. Approximately 15% of reported tuberculosis cases are culture 
negative, but these data are not available for HIV-infected cases. However, at 
San Francisco General Hospital, culture-negative tuberculosis in HIV-infected 
patients is seldom observed. (This perceived increase in sensitivity might be 
due in part to the increased use of diagnostic bronchoscopy in HIV-positive 
cases of suspected tuberculosis.) Unfortunately, culture results may not be 
available for 2-6 weeks, creating a need for more rapid diagnostic techniques.  
Nucleic acid amplification (NAA) tests detect nucleic acid sequences 
unique to organisms in the M tuberculosis complex, allowing for a rapid 
diagnosis. Two NAA tests, the Amplified Mycobacterium Tuberculosis Direct 
Test (MTD; Gen-Probe) and the Amplicor Mycobacterium Tuberculosis Test 
(Amplicor; Roche) have been approved by the U.S. Food and Drug 
Administration (FDA) for use in respiratory specimens in patients who have not 
previously been treated for tuberculosis. The MTD test is approved for use in 
smear-positive or smear-negative samples, whereas Amplicor is only approved 
for use with smear-positive samples. 
       A negative NAA test does not rule out the diagnosis of active 
tuberculosis, and antituberculous therapy and further diagnostic workup are 
needed if sufficient clinical suspicion for tuberculosis exists. The predictive 
value of NAA testing will vary depending on the sensitivity and specificity of 
the test in the local laboratory, as well as on the prevalence of M tuberculosis 
and other mycobacteria. Moreover, NAA testing does not provide information 
on drug resistance. NAA tests are an important addition to our armamentarium 
of diagnostic tools, but they do not replace AFB smear, culture, or, more 
importantly, clinical judgment. 
Diagnosis of Latent Tuberculosis Infection 
Screening for latent tuberculosis infection (LTBI) is an essential step in 
controlling the spread of tuberculosis. Screening for LTBI is recommended in 
persons at risk for recent infection and in those groups with increased risk of 
progression to active disease once infected, including HIV-infected persons. 
The tuberculin skin test (Mantoux method) is currently the only method 
available for identifying LTBI. Routine annual tuberculin skin testing is 
recommended in HIV-infected individuals. 
A reaction of >=5 mm induration is considered positive for HIV-infected 
patients and persons with other forms of severe immunosuppression, persons 
who are close contacts of infectious cases, and persons with abnormal chest 
radiographs consistent with tuberculosis.60. Use of the 5-mm cutoff is supported 
by a prospective study in the United States demonstrating that the risk of 
tuberculosis was significantly higher in HIV-infected persons with tuberculin 
skin test reactions >=5 mm of induration than in those who have a reaction <5 
mm.48  
 It is important to keep in mind that a negative tuberculin skin test does 
not exclude infection or active disease. Testing with tuberculin purified protein 
derivative is dependent on the presence of an intact cell-mediated immune 
response. In the setting of HIV infection, reduced cell-mediated immunity can 
lead to decreased delayed-type hypersensitivity (DTH) responsiveness, 
resulting in False-negative skin tests. In a multicenter study in the United 
States, the prevalence of a positive tuberculin skin test (>=5 mm) was shown to 
decrease with decreasing CD4 T-cell counts.61 
       Persons who are at risk for tuberculous infection (e.g., injection drug 
users, individuals who are institutionalized or from high-prevalence regions) 
should have a chest radiograph performed even if the tuberculin skin test is 
negative, particularly if their CD4 T-cell count is low. Annual chest radiographs 
should be considered in this high-risk group.  
 Application of multiple skin test antigens (e.g., Candida, mumps, tetanus 
toxoid, etc.), referred to as anergy testing, has been used to assess cell-mediated 
immune function and to distinguish true-negative from false-negative tuberculin 
skin test results. In 1991, the CDC recommended that anergy testing be 
performed in conjunction with tuberculin skin testing in HIV-infected persons 
based on the premise that anergic HIV-infected individuals at high risk for 
tuberculosis infection would benefit from treatment with INH. 62 In 1997, the 
CDC revised its recommendations and no longer recommends anergy testing 
while screening for M tuberculosis infection in HIV-infected persons. 63 The 
revised recommendation is based on the following points. First, there are no 
standardized guidelines for performing anergy skin testing. The appropriate 
number of control antigens to administer or the appropriate cut-off for 
interpreting a test as positive is not known. Second, the response to skin testing 
with control antigens as well as with tuberculin can vary over time. Several 
studies have demonstrated that HIV-1-seropositive individuals can regain DTH 
responsiveness with time. 64, 65, 66 In a multicenter study, Chin and colleagues66 
reported that 31% of anergic HIV-1-seropositive patients responded to DTH 
testing 1 year later. The only factor associated with regaining DTH 
responsiveness was the CD4 T-cell count: the higher the CD4 count, the more 
likely the individual was to regain DTH responsiveness. Finally, treatment of 
LTBI in anergic HIV-infected persons has not been demonstrated to be 
beneficial.67, 68  
In some individuals with tuberculous infection, DTH responsiveness may 
decrease with time. A second tuberculin skin test, applied weeks to months after 
the first, can "boost" the DTH response resulting in a positive skin test reaction. 
Such responses are considered true evidence of tuberculous infection. In a 
multicenter study in the United States, only 2.7% of HIV-1-seropositive 
patients "boosted" the tuberculin reaction with a second tuberculin skin test, 
despite relatively high demographic risk of tuberculous infection.69 However, a 
study in Uganda found that 17 (29%) of 58 HIV-1-infected subjects responded 
to a second tuberculin skin test.70  
Natural history  
Although the immune response to M tuberculosis is important in 
controlling disease, immune activation may also be associated with increased 
HIV viral load and accelerated progression of HIV infection. A retrospective 
cohort study in the United States found that although only one patient in the 
group died of tuberculosis, HIV-infected patients with tuberculosis do not 
survive as long as HIV-infected controls without tuberculosis, even after 
controlling for baseline CD4 T-cell count. When tuberculin-positive HIV-
infected patients were given INH therapy in Haiti, they were less likely to 
develop AIDS and less likely to die than patients given placebo. 71 Thus, it is 
likely that tuberculosis acts to accelerate the clinical course of HIV infection. 
Although increased viral replication is thought to play a role, the 
mechanisms by which tuberculosis accelerates progression of HIV disease are 
not known with certainty. High levels of tumor necrosis factor (TNF)-alpha, 
which are known to increase HIV replication in T-cell clones,72 have been 
demonstrated in both HIV-1-seropositive and -seronegative tuberculosis 
cases.73. 
 Moreover, Investigators have shown that M tuberculosis or purified 
protein derivative can also increase viral replication in infected T lymphocytes 
and monocytes.74-76A recent study demonstrated a 5- to 160-fold increase in 
viral replication during the acute phase of untreated tuberculosis.72 The clinical 
significance of this increase in viral load is uncertain. 
TREATMENT  
STANDARD TREATMENT REGIMENS  
Anti-TB therapy is equally effective in HIV-negative and HIV-positive 
patients. The weight of the evidence to date indicates that the rate of TB relapse 
after short-course (6-month rifamycin-based) therapy is similar for HIV-positive 
and HIV-negative patients, although this remains somewhat controversial.77,78. 
In general, then, the same treatment regimen may be used regardless of HIV 
status. The American Thoracic Society TB treatment guidelines (currently under 
revision) will likely include a recommendation to extend the duration of therapy 
to 9 months (regardless of HIV status) in persons who have both cavitary 
pulmonary disease on initial presentation and positive-sputum cultures after 2 
months of treatment. These changes are based on results of a recent TB-
treatment study conducted by the CDC, in which HIV-negative adults with 
pulmonary disease who met these criteria had a relapse rate of >20% -- far 
higher than the clinically acceptable relapse rate of <5%.79 
In TB-endemic areas, recurrent TB after completion of a course of 
therapy is more likely to be due to exogenous reinfection than to relapse.80. 
Compared with HIV-negative TB patients, co infected patients have a higher 
risk for recurrent TB, but this is due to reinfection rather than relapse.81 In a 
study conducted in Haiti, HIV-infected persons who completed a course of TB 
therapy were less likely to develop recurrent TB if they received a 12-month 
post-treatment course of isoniazid, compared with persons who received 
placebo.82 However, such practice has been implemented neither in developing 
countries (due to insufficient infrastructure) nor in developed countries (due to 
lower TB incidence rates and lower rates of exogenous reinfection).  
 
PHARMACOKINETIC INTERACTIONS  
A central aspect of TB treatment in HIV-infected patients is the 
pharmacokinetic interactions between rifamycins (e.g., rifampin and rifabutin) 
and PIs and NNRTIs. Although these interactions do not preclude the 
concomitant use of potent antiretroviral therapy and anti-TB therapy, clinicians 
must be aware of these interactions and adjust dosages accordingly. Although 
large studies of the effectiveness of rifabutin-based regimens in co infected 
patients concomitantly receiving antiretroviral therapy are underway, the results 
will not be available for 1 to 2 years. However, 2 small studies have 
demonstrated that rifabutin-based regimens are well tolerated and effective in 
such patients.83, 84  
DIRECTLY OBSERVED THERAPY  
Self-administered TB therapy has been compared with directly observed 
therapy in very few well designed, randomized, controlled studies; however, the 
available data indicate that directly observed therapy is associated with 
decreased rates of TB incidence and drug resistance85 and increased rates of 
sputum conversion and therapy completion.86 Among HIV-infected patients, 
directly observed therapy has been associated with improved survival.87 Because 
of these benefits, directly observed TB therapy is recommended by the 
American Thoracic Society, the CDC, and the WHO.88, 89  
The regimen of DOTS is as shown below: 
 
Category of  
Treatment 
Type of patient Regimen Sputum 
Examination        
CAT-I New sputum smear 
positive 
Seriously ill sputum-
negative 
Seriously -ill-EP
2 H3R3Z3E3/ 
4 H3R3 
0  2  4    6 
      3    5    7 
MONTHS 
CAT- II Sputum smear +  
Relapse, Failure 
,Treatment after 
Default  
3 H3R3Z3E3S3/ 
1 H3R3Z3E3/ 
5 H3R3E3. 
0  3   5    8 
      4    6      9 
CAT-III Sputum negative not 
seriously ill ,EP not 
seriously ill 
2 H3R3Z3/ 
4 H3R3 
0     2      6 
 
Abbreviations: 
H- INH, R- Rifampicin, Z- Pyrazinamide, E- Ethambutol, S-Streptomycin. 
 
 
 
 
HIV AND PARADOXICAL WORSENING OF TB  
Paradoxical worsening of TB is the development of new signs or symptoms of 
TB disease or the exacerbation of existing manifestations of TB in patients 
receiving appropriate anti-TB therapy. Diagnosis of paradoxical worsening 
requires that other possible explanations be excluded, such as treatment failure, 
drug resistance, poor compliance, malabsorption, adverse drug reactions, and 
lymphoma. Paradoxical worsening is thought to represent an improvement of 
the host's immune response to mycobacterial antigens during the course of 
treatment, leading to more intense inflammation at sites of TB disease.  
The estimated incidence of paradoxical worsening of TB in HIV-infected 
patients ranges from 7% to 36%, which is higher than the rate seen in HIV-
negative patients. In one hospital-based study, higher rates of paradoxical 
worsening in co infected patients were associated with the use of antiretroviral 
therapy.90 In a retrospective study of HIV-infected patients receiving outpatient 
TB treatment, the incidence of paradoxical worsening was not associated with 
the use of potent combination antiretroviral therapy, but patients experiencing 
paradoxical worsening while on antiretroviral therapy had a more severe and 
prolonged course. Paradoxical worsening of TB in HIV-infected patients has 
been associated with the presence of concurrent pulmonary and extrapulmonary 
TB at the time of initial diagnosis.91 
The course of paradoxical worsening can be brief or prolonged, with multiple 
recurrences and exacerbations. Corticosteroid treatment of severe episodes of 
paradoxical worsening has not been associated with progression of TB disease 
or failure of anti-TB therapy. Patients with less severe symptoms may obtain 
relief with nonsteroidal anti-inflammatory medications. Although antiretroviral 
therapy may be associated with the development or severity of paradoxical 
worsening, discontinuation of therapy is not generally recommended. 
TREATMENT OF LATENT TB INFECTION  
As noted above, the risk for progressing to active TB is high among HIV-
seropositive persons infected with M. tuberculosis. Therefore, all HIV-infected 
persons with evidence of latent M. tuberculosis infection should receive 
treatment. See Table 1 for the indications for treatment of latent infection in 
HIV-infected persons and potential treatment regimens. In a study among HIV-
infected persons with latent M. tuberculosis infection, 2 months of daily 
rifampin + pyrazinamide was as effective as 12 months of daily isoniazid in 
preventing active TB; both regimens were well tolerated.92 A recent study found 
that combination short-course regimens had a more durable protective effect 
than did isoniazid alone.93. However, there have recently been 6 hepatotoxicity-
associated deaths reported among persons taking daily rifampin + 
pyrazinamide.94, 95 Although none of the 6 persons was HIV-positive, the 
recommendations for the treatment of latent TB infection have been revised to 
state that this regimen should not be offered to patients with underlying liver 
disease or with prior isoniazid-associated hepatotoxicity. This regimen should 
be used with particular caution in patients concurrently taking other medications 
associated with liver injury and in those with a history of alcohol abuse. See 
Table 1 for recommendations for toxicity monitoring during treatment for latent 
TB infection.  
The WHO recommends treating latent M. tuberculosis infection in HIV-infected 
persons in the developing world. However, implementation of this policy has 
been incomplete due to limited resources in these settings. This is particularly 
true in settings in which resources are insufficient to identify and treat all 
persons with active TB, which remains a higher priority.    
 
 
 
 
 
WHO recommendations for the treatment of TB and HIV co infection with 
reference to CD-4 cell count. 
CD 4 cell count Recommended 
regimen  
Comments 
< 200 mm3 Start TB treatment. Start 
ART as soon as TB 
treatment is tolerated (2 
weeks to 2 months) 
EFV containing 
regimens. 
Recommended ART 
EFV is contraindicated in 
pregnant or women of 
childbearing potential 
without effective 
contraception 
200 to 350 mm3 Start TB treatment. start 
one of the below 
regimens after initiation 
phase: EFV containing 
regimens or NVP 
containing regimens in 
case of Rifampicin free 
continuation phase TB 
treatment regimen. 
Consider ART 
> 350 mm3 
 
Start TB treatment. 
 
Defer ART 
 
CD 4 count not available 
 
Start TB treatment. Consider ART 
 
 
Abbreviations: 
EFV- efavirenz, NVP – nevirapine. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
The age groups commonly affected by tuberculosis infection among 
the HIV seropositives range from 20 to 40 years. This corresponds to other 
studies, both foreign and Indian, like, S. Rajashekaran  et al. 96 who reports 
that the most common age group affected was between 21 to 40. 
Maheshwari et al, 97 and Nirgudkar et al, 98 have also recorded the highest 
incidence of HIV-TB co-infection in the third decade. 
Among the 347 patients infected with HIV infection, sixty-nine was 
having TB co-infection. Out of these sixty-nine patients, 68.11% were 
males, 26.08% were females and 5.8% were children. This indicates that the 
Male: Female ratio is 2.5:1. The incidence of TB co-infection in children is 
alarmingly high and more efforts are needed to prevent the congenital HIV 
infection and also to screen the HIV cases periodically for Tuberculosis 
infection. 
The prevalence of HIV is more in the fourth decade (45.37%). The 
average age of the population is 33.3 years. This indicates that the 
economically productive group of the population is at the greatest risk of 
tuberculosis HIV co-infection thereby causing heavy loss to the society at a 
large. 
Agricultural laborers were more commonly affected with HIV TB co-
infection when compared to others. This indicates that the problem is more 
common in the economically backward groups in which malnutrition; 
overcrowding, hi-risk sexual practices are seen. 
Immune Reconstitution Syndrome was observed in one case that 
developed lower lobe infiltration after starting ART with the anti 
tuberculous therapy for pleural effusion. This shows the enhancement of 
cell-mediated immunity. 
  Miliary mottling, diffuse infiltration, hilar-adenopathy and non-
cavitary lesions were common in severe immunosuppression, CD4+ counts 
< 100. Upper lobe lesions were more common in early immuno-suppression, 
which is similar to the reports of the previous studies.  
Anergy to Tuberculin skin testing was noted in thirty-five out of the 
sixty-nine patients studied (50.72%). This correlates well with the earlier 
studies by Johnson et al., 99 Huebner et al., 100 and the Baltimore based 
study- Graham et al., 101 Jones et al., 102 Mukadi et al., 103 which show an 
increased incidence of anergy in HIV infected and the AIDS patients.  
Analysis of the clinical presentation showed the following findings, 
Fever was the most common clinical presentation followed by loss of 
appetite and cough. This finding corresponds to that of the earlier 
observations of Modilevsky et al., 104 and the Bellevue hospital study,  both 
reported that fever and cough were the predominant symptoms in TB- HIV 
co-infection patients. The registry of AIDS patients at NACO  also shows 
that fever, cough and weight loss as the commonest symptoms. 
Symptom 
analysis 
Our study Rajasekaran S 
et al, 
Beenasusheel 
and Pai et al, 
Modilevsky 
et al, 
NACO 
Registry. 
 Fever, cough 
and loss of 
appetite and 
weight are 
common 
symptoms. 
Fever, cough 
with 
expectoration 
loss of 
appetite and 
weight- 
common 
symptoms. 
Fever and 
cough are the 
most 
consistent 
symptoms 
Fever and 
cough are the 
common 
symptoms. 
 
 
The sputum positivity in our study shows that only 22 percent of the 
individuals are sputum positive. This correlates well with other studies as 
discussed below, 
Sputum culture for Mycobacterium tuberculosis remains the gold 
standard for the diagnosis of Pulmonary TB. In resource-poor countries the 
diagnosis is heavily dependent on the sputum AFB smear. HIV infected 
patients have been reported to have a lower yield on AFB smears. Brindle 
ea al., 105 observed that HIV positive patients excreted slightly fewer 
organisms per milliliter of sputum than did HIV negative patients with 
culture confirmed TB. Positive smears were observed in 31 to 89% of 
patients. Klein et al., 106 reported only21% of smear positive cases in HIV 
infected patients compared to 35% in HIV negative patients. Kramer 107 
reported an increase in the yield of smears when repeated up to five times.   
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The results of fiber optic bronchoscope derived samples for smear 
examination are variable. Miro et al 108 reported an increase in the yield of 
smears in broncho alveolar lavage specimen, though statistically 
insignificant. The results of Kennedy et al, 109 Salzmann et al, 110 showed a 
statistically significant increase in the yield of smears for AFB in broncho 
alveolar lavage specimens.    
Smear positivity varied with the nature of X- ray lesion occurrence of which 
in turn depends on the immune status of the individual. Greenbaum et al 
reported 52% positive smears with cavitary disease and only 32% positives 
in local infiltrates. Barnes et al, 111 found positive smears in 90% of patients 
with radiographic findings typical of adult reactivation and in 98% of 
patients with cavitary TB.  
 
In our study, a CD 4+ cell count < 200 was observed in 45 out of the sixty-
nine patients. In these patients, the predominant X-ray lesions were hilar 
adenopathy, lower lobe infiltrations, diffuse infiltrations and miliary 
mottling. This finding correlates well with the studies conducted in south 
Africa by Post FA Wood, R Pillay et al,112 in this study the lower zone 
infiltration and hilar adenopathy were common with lower CD4 + counts- 
mean value of 105. Upper lobe infiltration was common with higher CD 4+ 
counts- mean 389. Similar results were published by several studies like the 
one in NEJM Feb 4, 1999. David Perlman et al 113 reported increased 
incidence of hilar adenopathy with advanced immuno-suppression.   
In our study most of the patients fall under stage III of the WHO staging 
system (thirty five out of the sixty-nine patients- 50.72%) 
Pulmonary Tuberculosis infection is reported in stage III of the WHO 
guidelines.  
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RESULTS: 
 
The study population was derived from the persons attending outpatient 
department at Thanjavur Medical College and the attached Raja Mirasudar 
Hospital. Out of the 347 confirmed cases of HIV infection 69 persons were 
found to be suffering from pulmonary tuberculosis, they formed the study 
population. 
The prevalence of pulmonary tuberculosis in HIV was 69 out of 347 i.e. 
19.88%  
347
69
total no of
persons with
HIV
no of persons
with PT
 
 
 
 SEXWISE DISTRIBUTION: 
Out of the 69 patients with TB and HIV co infection 47(68%) were males 
18(26%) were females and 4(6%) were children. 
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AGE: 
The age wise distribution of cases was as follows: 
Age group Male Female 
0to 20 1(1.4%) 4(5.8%) 
21to 30 11(16%) 10(14.5%) 
31 to 40 28(40.5%) 4(5.8%) 
41 and above 8(11.5%) 3(4.3%) 
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 SYMPTOMS: 
The symptoms present in patients of the study group are as follows: 
Symptoms Number 
Fever 69 (100%) 
Cough 57 (82.6%) 
Loss of weight  68 (98.5%) 
Recurrent diarrhea  20 (29%) 
Weakness 29 (42%) 
Skin manifestations, oral thrush 4 (5.8%) 
Hemoptysis 3 (4.3%) 
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SPUTUM POSITIVITY: 
The result of 2 spot and one early morning sputum microscopic examination 
for acid-fast bacilli is as follows: 
Positive 15(21.74%) negative 54(78.26%) 
15
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The occupation of patients is as follows: 
 
 
 
Occupation Number 
Agriculture 33 (47.8%) 
Housewife 10 (14.5%) 
Businessman 9(13%) 
Driver 7 (10%) 
Skilled laborer 5 (7.2%) 
Others 5 (7.2%) 
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The Mantoux test results are as follows: 
 
Mantoux reading (mm) Number 
0 to 4 23 (33.3%) 
5 to 9 12 (17.4%) 
10 to 14 19 (27.5%) 
15 to 19 10 (14.5%) 
20 and above 5 (7.2%) 
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The CD 4 cell count in patients was as follows: 
 
 
CD 4 count Number 
0 to 100 24 (34.8%) 
101 to 200 21 (30.4%) 
201 to 300 15 (21.7%) 
301 and above 9 (13%) 
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WHO clinical staging: 
The patients’ distribution according to the WHO clinical stage is as follows; 
 
 
WHO stage Number 
I 11 (16%) 
II 14 (20.3%) 
III 35 (50.7%) 
IV 9 (13%) 
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The distribution of X ray lesions in the study population is as follows: 
Site of lesion Number 
Upper zone  11 (15.9%) 
Upper and mid zone 3 (4.3%) 
Mid zone 3 (4.3%) 
Lower zone  15 (21.7%) 
Diffuse infiltration  8 (11.6%) 
Military mottling 5 (7.2%) 
Pleural effusion 6 (8.7%) 
Cavity 3 (4.3%) 
Hilar lymphadenopathy 14 (20.2%) 
Normal 1 (1.4%) 
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The average Mantoux in mm in relation to CD4+ cell counts is as follows, 
 
 
 
CD 4 + COUNT AVERAGE MANTOUX 
READING (in mm) 
0 - 100 3.2 
101- 200 9.4 
201- 300 14.4 
> 300 17.4 
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The Sputum AFB status in relation to the CD4+ cell counts is as follows, 
 
CD 4 + COUNT SPUTUM POSITIVES SPUTUM NEGATIVES
0 - 100 5 (7.2%) 19 (27.5%) 
101- 200 3 (4.3%) 18 (26.1%) 
201- 300 5(7.2%) 10 (14.5%) 
> 300 2(2.9%) 7 (10.1%) 
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Chest X-ray findings observed in relation to the CD4 + cell counts is as 
follows,  
 
CD4+ 
COUNT 
UPP.Z UPP-
MID   
Z 
MID.Z LO.Z DIFF MIL PL.EFF CAV HA NOR
0-100 2 3 1 5 5 5 1 0 2 0 
101-200 1 0 0 7 3 0 1 1 8 0 
201-300 5 0 2 2 0 0 3 1 1 1 
>300 3 0 0 1 0 0 1 1 3 0 
 
 
UPP.Z: Upper Zone UPP-MID Z: Upper and middle Zone  MID.Z: Middle Zone  
LO.Z: Lower Zone DIFF: Diffuse infiltrates MIL: Miliary Mottling PL.EFF: Pleural 
Effusion CAV: Cavity HA: Hilar Adenopathy NOR: Normal. 
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The most common side effect of drug therapy was gastritis. Minor skin 
rashes were observed after starting ART. One case of Immune 
Reconstitution Syndrome was observed. 
CONCLUSION 
 
Pulmonary Tuberculosis is a common opportunistic infection among the 
HIV seropositive individuals. 
 
Pulmonary Tuberculosis occurs early in the HIV infection even before the 
CD 4+ count falls to very low levels. 
 
Males are more commonly affected than females. 
 
Agricultural workers and the low income group were commonly affected. 
 
Fever, cough and loss of appetite and weight were the most common 
symptoms observed in HIV-TB co-infection. 
 
Sputum negativity was more commonly seen in Pulmonary tuberculosis of 
HIV seropositive individuals.  
 
Mantoux anergy was observed with lower CD 4+ counts. 
Pattern of Primary Tuberculosis infection was seen in the X-ray of HIV 
seropositive individuals with TB co-infection in the lower CD 4+ count 
groups. A pattern of post-primary pulmonary tuberculosis was seen in the 
more immunocompetent group. 
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